Search
for
Sort by
Research 271–300 of 1000+
- An Assessment of the Safety, Efficacy, and Tolerability of a Novel Scalp Treatment Regimen Combining a Hydroxy Acid-Based Scrub and Copper Tripeptide Serum in the Management of Seborrheic Dermatitis in Adults
- Efficacy and safety of non‐cross‐linked hyaluronic acid compound in the treatment of keratosis pilaris: A split‐body randomized clinical trial
- Efficacy and Safety of an Autologous Micrografting Procedure for Management of Striae Distensae in Women
- Efficacy and safety of metformin for melasma treatment: a systematic review and meta-analysis
- Efficacy and safety of baricitinib in patients with refractory alopecia areata
- Efficacy and safety of 1565-nm non-ablative fractional laser versus long-pulsed 1064-nm Nd:YAG laser in treating enlarged facial pores
- The Clinical Efficacy and Safety of Autologous Activated Platelet-Rich Plasma Injection in Androgenetic Alopecia
- USING HAIR GROWTH ACTIVITY, PHYSICAL STABILITY, AND SAFETY TESTS TO STUDY HAIR TONICS CONTAINING ETHANOL EXTRACT OF LICORICE (GLYCYRRHIZA GLABRA LINN.)
- Efficacy and safety of 5% minoxidil topical foam in male pattern hair loss treatment and patient satisfaction
- The Efficacy and Safety Human Study of Narasoo Healing Shampoo and Hair Tonic for Scalp's Lipids & Moisture and Hair Growth -One Center, one group pre-post comparison Pilot Human study-
- Off-label prescriptions: patient safety first
- Efficacy and safety of Cinainu in paediatric alopecia areata: an international, double-blind, randomized, placebo-controlled, phase II/III trial
- Efficacy and safety of tofacitinib in the treatment of adults with lichen planopilaris: A randomized placebo-controlled trial
- Comparative efficacy and safety of systemic steroids, oral JAK inhibitors and Contact Immunotherapy in the Treatment of severe alopecia areata: a systematic review and network meta-analysis
- Efficacy and Safety of Platelet-Rich Plasma in Melasma: A Systematic Review
- Efficacy and Safety of Topical Flutamide 1% Gel as an Adjunctive Therapy in the Treatment of Patients With Acne Vulgaris
- 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
- LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)
- Efficacy and Safety of Tracnil™ Administration in Patients with Dermatological Manifestations of PCOS: An Open-Label Single-Arm Study
- Automatic Artificial Hair Implant: Safety and Efficacy in Androgenetic Alopecia. A Prospective Study with a Highly Biocompatible Fiber
- Non-clinical safety evaluation and risk assessment to human of aleglitazar, a dual PPAR α/γ agonist, and its major human metabolite
- Efficacy and Safety of a Food Supplement Containing L-cystine, Serenoa repens Extract and Biotin for Hair Loss in Healthy Males and Females. A Prospective, Randomized, Double-blinded, Controlled Clinical Trial
- Efficacy and Safety of Minoxidil 5% Foam in Combination With a Botanical Hair Solution in Men With Androgenic Alopecia.
- Human Dermal Safety Studies with Eflornithine HCl 13.9% Cream (Vaniqa™), a Novel Treatment for Excessive Facial Hair
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- Integration of Colorimetric Sensing Dyes and Multi‐Substrate Arrays for Food Quality and Safety Monitoring: Design, Optimization, and Analysis
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Efficacy and safety of JAK inhibitors in treating lichen planopilaris or frontal fibrosing alopecia
- Efficacy and safety of compound glycyrrhizin combined with topical minoxidil for alopecia areata: a systematic review and meta-analysis of randomized controlled trials
- 54022 Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata